Mitochondria and clotting risk in lupus
Role of mitochondria in SLE and its cardiovascular complications
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11138661
This project looks at whether immune reactions to damaged mitochondria in people with lupus are linked to blood clots and other heart and blood vessel problems.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11138661 on ClinicalTrials.gov |
What this research studies
This work will follow 500 people with systemic lupus erythematosus over time to see if a specific mitochondrial antibody (called AMA-17) shows up before or with venous blood clots. In the lab, researchers will study how damaged mitochondria expose the mitochondrial protein targets and whether blocking mitochondrial reactive oxygen species can prevent those targets from forming. Purified AMA-17 antibodies will be tested on platelets and in engineered microvessels to see if they trigger clotting. The overall aim is to find whether a blood test or mitochondrial-directed treatments could help predict or reduce clot risk in lupus.
Who could benefit from this research
Good fit: Ideal candidates are adults with a diagnosis of systemic lupus erythematosus who can provide blood samples and attend periodic clinic visits for long-term follow-up.
Not a fit: People without lupus or whose clots are caused by unrelated conditions may not benefit from the findings of this project.
Why it matters
Potential benefit: If successful, this could lead to a blood test to identify lupus patients at higher risk of clots and point to new treatments that target mitochondrial processes.
How similar studies have performed: There is prior evidence that autoantibodies can drive clotting in lupus, but using a mitochondrial antibody (AMA-17) and engineered microvessel models is a relatively new and novel approach.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LOOD, JAN CHRISTIAN — UNIVERSITY OF WASHINGTON
- Study coordinator: LOOD, JAN CHRISTIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Phospholipid Antibody Syndrome, Anti-phospholipid Syndrome